Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,713 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 26 more
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, GW677954
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Colesevelam, Placebo, Pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 114 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

NCT02496221
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide 50 mg, Placebo, CCK (Kinevac)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies

NCT03047447
Conditions
Metabolic Syndrome, Diabetes Mellitus, Type 2, Pre Diabetes
Interventions
Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
Behavioral
Lead sponsor
Bristlecone Behavioral Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Maple Grove, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes

NCT01926938
Conditions
Obesity, Insulin Resistance
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Insomnia, Diabetes Mellitus, Type 2
Interventions
Insomnia Intervention, Information Control
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Type2 Diabetes
Interventions
BT-001
Device
Lead sponsor
Better Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Plano, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Dapagliflozin, Glimepiride
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Glimepiride, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Completed Not applicable Interventional Results available

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439
Conditions
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions
Exenatide, Glargine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 2 Diabetes
Interventions
GEM Intervention
Behavioral
Lead sponsor
Catherine Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Augusta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers

The Diabetes TeleCare Study

NCT00288132
Conditions
Diabetes Mellitus, Type 2
Interventions
Intervention, Usual Care
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bennettsville, South Carolina
Terminated Phase 3 Interventional Results available

Effect of Efpeglenatide on Cardiovascular Outcomes

NCT03496298
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide (SAR439977), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
79
States / cities
Sheffield, Alabama • Gilbert, Arizona • Surprise, Arizona + 69 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Supervised walking on a treadmill, Supervised stretching exercise
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fayetteville, Arkansas
Conditions
Diabetes, Executive Dysfunction
Interventions
Cholecalciferol
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Chronic Kidney Diseases, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Newark, Delaware • Nampa, Idaho + 2 more